Drugs Made In America Acquisition Corp. 8K

DMAA and PAGC amended their merger agreement to overhaul SPAC capitalization and financing terms, set minimum cash and timeline parameters, and lay out a contingent structure for adding a third target, with added safeguards for related‑party conflicts.

On July 14, 2026, Drugs Made In America Acquisition Corp. (DMAA) and Power Analytics Global Corp. (PAGC) executed Omnibus Amendment No. 3 to their April 29, 2026 Definitive Merger Agreement, comprehensively resetting DMAA’s SPAC capital structure and financing framework for the proposed business combination, including large sponsor and founder share forfeitures and earnouts, resolution of rights and underwriter economics, confirmation and restatement of minimum cash and permitted financings, acknowledgment of substantial prior redemptions, and the establishment of process and timing for a potential three-party combination via a pre-approved but contingent Amendment No. 4 with an unnamed “Additional Target,” while also embedding enhanced related‑party protections (fairness opinion and independent director oversight) due to common ownership links between PAGC and BV Advisory Partners, LLC.

Filing Facts

CIK

2028614

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-079678

Alert Tier

8